Life Sciences

Guy Mayer's Recommendation of Bob JohnstonGuy Mayer: Chairman of OMNILife Science, CEO of Ascension Orthopedics and CEO of Tutogen Medical "As a CEO/Chairman, I have had the pleasure of hiring and working with Bob on 3 different occasions as EVP at OMNILife Science, CFO/COO at Ascension Orthopedics and CFO at Tutogen Medical. As a key trusted partner for me, I could always depend on Bob to successfully execute to our plan, be a strong Executive strategic leader… Show more Guy Mayer's Recommendation of Bob JohnstonGuy Mayer: Chairman of OMNILife Science, CEO of Ascension Orthopedics and CEO of Tutogen Medical "As a CEO/Chairman, I have had the pleasure of hiring and working with Bob on 3 different occasions as EVP at OMNILife Science, CFO/COO at Ascension Orthopedics and CFO at Tutogen Medical. As a key trusted partner for me, I could always depend on Bob to successfully execute to our plan, be a strong Executive strategic leader, communicator and motivator, great team player and mentor. He is the consummate Executive and seasoned CFO that, without reservation, I would highly recommend." OMNILife Science experience for Bob Johnston:As an Executive leader, I assisted in the successful acquisition of OMNI by Corin in March 2019, Inc, working closely with Piper Jaffray and management to explore the sale and providing executive sales and organizational leadership to make substantial improvements. With the sale of the company, my position was eliminated.►Reenergized sales to record levels with double digit growth monthly, following the VP of Sales’ retirement in Feb. 2018. October 2018 was a record month in domestic sales in the 20 year history of the company.►Tripled the number of surgeons using our proprietary robotic technology in 7 months, leading a cross-departmental project team.►Helped save the company $4.8 million in an 11 month period by working closely with the VP of Operations to retrieve underutilized assets in the field to be redeployed. Show less

Atlas Genetics (now Binx Health) was a pioneer in point-of-care testing solutions. I brought my broad experience in the life sciences industry to provide key leadership to this early stage company. In January 2017, I managed a $35 million equity financing with lead strategic Chinese investor, Wondfo Biotech, working closely with NYC investment bank, UBS, and the CEO to successfully close the transaction. Upon completion of the financing, the CEO transitioned and my position was… Show more Atlas Genetics (now Binx Health) was a pioneer in point-of-care testing solutions. I brought my broad experience in the life sciences industry to provide key leadership to this early stage company. In January 2017, I managed a $35 million equity financing with lead strategic Chinese investor, Wondfo Biotech, working closely with NYC investment bank, UBS, and the CEO to successfully close the transaction. Upon completion of the financing, the CEO transitioned and my position was transitioned.►Saved company $1 million in first 12 months►Oversaw transferring audited financials from UK GAAP to IFRS with auditors at PWC►Instrumental in completing agreement with key manufacturing vendor Show less

I made a significant impact in improving the performance of this medical device company. Within 6 months of hire, I played an instrumental role in completing a $30 million debt refinancing, which greatly enhanced the company’s financial position. My promotion of the company on Wall Street resulted in increased analyst coverage and multiple new institutional investors.► Completed $15 million equity raise including bringing lead (Deerfield) to company► Directly helped expand the… Show more I made a significant impact in improving the performance of this medical device company. Within 6 months of hire, I played an instrumental role in completing a $30 million debt refinancing, which greatly enhanced the company’s financial position. My promotion of the company on Wall Street resulted in increased analyst coverage and multiple new institutional investors.► Completed $15 million equity raise including bringing lead (Deerfield) to company► Directly helped expand the U.S. sales force and surgeon educational events, resulting in triple the sales growth in 15 months. Sales had been flat for several quarters prior to my arrival Show less

In close collaboration with the CEO, I was instrumental in successfully completing the very complicated and intensive acquisition of Scientific Protein Laboratories by a public Chinese manufacturer of heparin (Hepalink), providing key leadership and communications with senior management throughout the project. Over 6 months, I led extensive due diligence efforts with the acquiring entity and its 8 advising firms (two investment banks, two Chinese auditors, two legal firms, Chinese valuation… Show more In close collaboration with the CEO, I was instrumental in successfully completing the very complicated and intensive acquisition of Scientific Protein Laboratories by a public Chinese manufacturer of heparin (Hepalink), providing key leadership and communications with senior management throughout the project. Over 6 months, I led extensive due diligence efforts with the acquiring entity and its 8 advising firms (two investment banks, two Chinese auditors, two legal firms, Chinese valuation firm and Chinese securities firm), and oversaw the completion of two interim audits conducted by a Chinese auditor. Ultimately, this position was eliminated. Show less

I brought a wealth of financing and operations executive experience to help turn around this struggling company and working closely with the CEO and UBS completed a $65 million acquisition by Integra LifeSciences. Ultimately, this position was eliminated. ►Capitalized on a variety of business opportunities with CEO and other Senior management; enhanced key vendor relationships►Negotiated, structured and completed $9 million in venture debt financing and $18 million in debt… Show more I brought a wealth of financing and operations executive experience to help turn around this struggling company and working closely with the CEO and UBS completed a $65 million acquisition by Integra LifeSciences. Ultimately, this position was eliminated. ►Capitalized on a variety of business opportunities with CEO and other Senior management; enhanced key vendor relationships►Negotiated, structured and completed $9 million in venture debt financing and $18 million in debt financing Show less

While integrating Tutogen Medical, I secured over $12M in financing and captured millions of dollars in acquisition cost savings.►Oversaw 30-person finance/accounting teams in U.S. and Germany. Position eliminated upon completion of integration/financing.►Closed $11.75M debt deal (Mercantile Bank) in difficult market, saving $450K in annual fees and interest costs►Established $900K in euro debt financing in Germany with HypoVereinsbank

With the CEO and senior management, turned around the struggling public medical device company to profitability, and grew the $35M company to $260+ valuation. Worked closely with Cowen on the successful sale of the company. The CFO position was eliminated after $263M sale and I moved to the parent company to support the integration.► Marketed the company with CEO at roadshows; persuaded three new research analysts to initiate coverage and increased institutional investor base from three to… Show more With the CEO and senior management, turned around the struggling public medical device company to profitability, and grew the $35M company to $260+ valuation. Worked closely with Cowen on the successful sale of the company. The CFO position was eliminated after $263M sale and I moved to the parent company to support the integration.► Marketed the company with CEO at roadshows; persuaded three new research analysts to initiate coverage and increased institutional investor base from three to 30 in 12 months► Oversaw extensive Sarbanes-Oxley (SOX) process in U.S. and Germany with no issues, advised by Grant Thorton► Completed $12M PIPE (Roth Capital), $3.0M convertible debt financing, and $2M+ in German bank Euro debt financings► Working with senior leadership team, landed key deals for global dental distribution (Zimmer), U.S. distribution (Mentor), global urology (Coloplast), and key tissue sourcing deal (RTI Biologics) Show less

Instrumental in strategic financing agreements and build-out of national sales force and corporate manufacturing and distribution deals, I dramatically enhanced financial position of Power Medical with $35M Series B financing with Boston Scientific and complex $10M venture debt deal with GE/Hercules.►Working alongside the CEO, completed strategic Japanese distribution deal

Along with the CEO, I transformed this early-stage start-up from pre-revenue to emerging global player. Initiated commercialization of drug screening platform; closed deals with top ten global pharma companies in just 18 months. Grew revenue from zero to ~$20M in two years.► Positioned company for IPO (Prudential, ING Barings, and Dain Rauscher), IPO postponed due to market conditions► Secured $55M in financing via preferred stock transactions, $6M in equipment financing from… Show more Along with the CEO, I transformed this early-stage start-up from pre-revenue to emerging global player. Initiated commercialization of drug screening platform; closed deals with top ten global pharma companies in just 18 months. Grew revenue from zero to ~$20M in two years.► Positioned company for IPO (Prudential, ING Barings, and Dain Rauscher), IPO postponed due to market conditions► Secured $55M in financing via preferred stock transactions, $6M in equipment financing from Transamerica and Oxford Finance, and equity investment from key strategic partner (Beckman Coulter)►Helped structure, negotiate and complete key business deals with Beckham Coulter, Zeiss, ACLARA Biosciences, Molecular Probes and several pharmaceutical collaborations and academic licensing arrangements. Show less

I worked with President to restructure the pioneering genetic testing company and complete several business deals for genomic databases (Incyte-included $3M strategic investment), gene chip tech (Affymetrix), clinical study data, gene rights IP, and reagents. With the CEO, President, and Hambrecht Quist, negotiated and closed $40M merger/sale; CFO role was eliminated.► Played key role in the IPO , and Secondary Offering (Jefferies and Co and Rodman Renshaw)► Entered pharmacogenomic… Show more I worked with President to restructure the pioneering genetic testing company and complete several business deals for genomic databases (Incyte-included $3M strategic investment), gene chip tech (Affymetrix), clinical study data, gene rights IP, and reagents. With the CEO, President, and Hambrecht Quist, negotiated and closed $40M merger/sale; CFO role was eliminated.► Played key role in the IPO , and Secondary Offering (Jefferies and Co and Rodman Renshaw)► Entered pharmacogenomic deals with category leaders Rhone-Poulenc Rorer, Schering-Plough, and Merck► Divested the genetic testing service unit to Myriad Genetics Show less